193 related articles for article (PubMed ID: 32269775)
1. An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children.
Kantar A; Klimek L; Cazan D; Sperl A; Sent U; Mesquita M
Multidiscip Respir Med; 2020 Jan; 15(1):511. PubMed ID: 32269775
[No Abstract] [Full Text] [Related]
2. Safety of ambroxol in the treatment of airway diseases in adult patients.
Cazan D; Klimek L; Sperl A; Plomer M; Kölsch S
Expert Opin Drug Saf; 2018 Dec; 17(12):1211-1224. PubMed ID: 30372367
[TBL] [Abstract][Full Text] [Related]
3. Ambroxol in the 21st century: pharmacological and clinical update.
Malerba M; Ragnoli B
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1119-29. PubMed ID: 18680446
[TBL] [Abstract][Full Text] [Related]
4. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood.
Paleari D; Rossi GA; Nicolini G; Olivieri D
Expert Opin Drug Discov; 2011 Nov; 6(11):1203-14. PubMed ID: 22646987
[TBL] [Abstract][Full Text] [Related]
5. Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive?
Scaglione F; Petrini O
Clin Med Insights Ear Nose Throat; 2019; 12():1179550618821930. PubMed ID: 30670922
[TBL] [Abstract][Full Text] [Related]
6. Polypharmacology of ambroxol in the treatment of COVID-19.
Wang Z; Yang M; Chen X; Xiao R; Dong Y; Chu M; Song G; Wang Y
Biosci Rep; 2023 Feb; 43(2):. PubMed ID: 36651548
[TBL] [Abstract][Full Text] [Related]
7. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study.
Schulz M; Hämmerlein A; Hinkel U; Weis G; Gillissen A
Int J Clin Pharmacol Ther; 2006 Sep; 44(9):409-21. PubMed ID: 16995329
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro analysis of inhibition of rhinovirus and influenza virus replication by mucoactive secretolytic agents and plant extracts.
Walther C; Döring K; Schmidtke M
BMC Complement Med Ther; 2020 Dec; 20(1):380. PubMed ID: 33357221
[TBL] [Abstract][Full Text] [Related]
9. Ambroxol for neuropathic pain: hiding in plain sight?
Russo MA; Baron R; Dickenson AH; Kern KU; Santarelli DM
Pain; 2023 Jan; 164(1):3-13. PubMed ID: 35580314
[TBL] [Abstract][Full Text] [Related]
10. Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome.
Gonzalez Garay AG; Reveiz L; Velasco Hidalgo L; Solis Galicia C
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD009708. PubMed ID: 25361381
[TBL] [Abstract][Full Text] [Related]
11. Inhaled mucoactive particles with tailored architecture for enhanced aerodynamicity, stability and efficacy.
Lee SH; Heng D; Teo JWP; Toh FKY; Tan RBH
Int J Pharm; 2019 Dec; 572():118740. PubMed ID: 31648015
[TBL] [Abstract][Full Text] [Related]
12. Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations.
Kardos P; Beeh KM; Sent U; Mueck T; Gräter H; Michel MC
BMC Pharmacol Toxicol; 2018 Jul; 19(1):40. PubMed ID: 29973292
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol.
Matthys H; de Mey C; Carls C; Ryś A; Geib A; Wittig T
Arzneimittelforschung; 2000 Aug; 50(8):700-11. PubMed ID: 10994153
[TBL] [Abstract][Full Text] [Related]
14. Mucoactive agents for adults with acute lung conditions: A systematic review.
Tarrant BJ; Maitre CL; Romero L; Steward R; Button BM; Thompson BR; Holland AE
Heart Lung; 2019; 48(2):141-147. PubMed ID: 30409442
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of acute bronchitis treatment in adults--a comparison of Bronchosol® syrup and synthetic preparations with ambroxol. Results of observational study].
Fal AM; Schönknecht K
Wiad Lek; 2015; 68(2):139-44. PubMed ID: 26181148
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty.
Zheng Z; Yang K; Liu N; Fu X; He H; Chen H; Xu P; Wang J; Liu M; Tang Y; Zhao F; Xu S; Yu X; Han J; Yuan B; Jia B; Pang G; Shi Y; Kuang M; Shao H; Xiong H; He J; Pan Y; Chen R
Front Med (Lausanne); 2023; 10():1182602. PubMed ID: 37305123
[TBL] [Abstract][Full Text] [Related]
17. Ambroxol for the prevention of acute upper respiratory disease.
Nobata K; Fujimura M; Ishiura Y; Myou S; Nakao S
Clin Exp Med; 2006 Jun; 6(2):79-83. PubMed ID: 16820995
[TBL] [Abstract][Full Text] [Related]
18. [More than expectorant: new scientific data on ambroxol in the context of the treatment of bronchopulmonary diseases].
Plomer M; de Zeeuw J
MMW Fortschr Med; 2017 Jun; 159(Suppl 5):22-33. PubMed ID: 28643291
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of ambroxol, a bronchial secretolytic agent, on gastric mucus in man.
Guslandi M; Zanoni ME
J Int Med Res; 1985; 13(5):281-3. PubMed ID: 4054429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
